Medtech

This year's top 100 ranking of global medtechs by revenue shows how industry leaders are aligning innovation with market trends to meet user and patient needs, while also managing their portfolios for growth.


View Rankings

Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way

 
• By Ashley Yeo

Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.

Global Medtech Recovers Core Growth After A Year Like No Other

 
• By Ashley Yeo

With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies.

Newer Therapy Areas Will Drive Women’s Health Funding In 2024

 
• By Marion Webb

Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.

Macro Challenges Make Calls On Newly Resilient Medtechs

 
• By Ashley Yeo

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

MTI 100 Company Rankings

Medtech Insight’s MTI 100 comprises a set of industry league tables providing US dollar rankings of medtech companies according to their overall annual medical device and IVD revenues where appropriate, and product sector-specific revenues where possible.

The 2023 MTI 100 list reflects a below-average level of M&A activity. The threshold for inclusion rose to half a billion US dollars for the first time. Several new names – many of them China-based IVD and other medical device manufacturers – have entered the lower reaches of the Top 100.

The table also reflects the winding out of COVID-based revenues, especially among IVD players – with the top ten companies Abbott and Roche the most visible examples of this.

Industry restructuring for faster growth and shareholder value creation predominate the thoughts of the leading players, and also many of those lower down the Top 100 ranking who are seeking rapidly to exploit the transformation of healthcare delivery, be it a place-based shift or by means of technology-driven innovations that are increasingly AI-enabled.

Figures shown are for the year ended 31 December 2023, except where noted, while most Japanese companies’ 31 March 2024 year-ends are reflected.

Unless noted, the Top 100 and key industry subsector tables show reported external medtech-specific sales values of publicly owned companies at manufacturer level and exclude service revenues unless noted. Average annual exchange US dollar exchange rates from 31 December 2023 are used for comparative purposes, regardless of the company’s financial year end.

For more information contact Ashley.Yeo@citeline.com